Strategic Fit Latham BioPharm Group (LBG) operates at the intersection of life sciences and consulting, recently integrated into Sia Partners’ life sciences division. This creates a compelling opportunity to pitch expanded, cross‑sell services such as strategic product development, regulatory strategy, and non-dilutive funding support to a combined client base across pharma, biotech, CROs, academia, and medical device sectors.

Funding Levers Core services include non-dilutive funding, presenting a clear sale path to clients seeking grant and award support, government programs, and early-stage funding. Approach potential clients with packaged funding advisory offerings aligned to product development timelines and regulatory milestones to accelerate portfolio progression.

Global Growth Recent acquisition by Sia Partners and the formation of a dedicated life sciences division signal access to broader global clients and projects. This opens opportunities to present integrated solutions across regions, leveraging Sia Partners’ Consulting 4.0 capabilities, AI, and CSR initiatives to deliver scalable, end‑to‑end life sciences programs.

Innovation Spotlight LBG has a track record with high-impact programs, including live biotherapeutic product development and a DARPA-funded initiative, which positions them as a capable partner for ambitious, high‑tech life sciences programs. Use this to target organizations pursuing advanced modalities and defense‑related or government‑funded collaborations.

Engagement Pathways With a revenue range of 50–100 million and a leaner team size, LBG may be seeking scalable partnerships, strategic alliances, and co‑selling opportunities with larger firms in the ecosystem (e.g., contract research organizations, device manufacturers, and large consultancies). Propose joint go‑to‑market programs and data-driven value propositions to win multi‑year engagements.